ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryPlan-Les-OuatesNovImmune SA
NovImmune SA Logo
Verified· 4 sourcesTrust Score
Summary

About the company

The core activity of NovImmune SA is the development of antibodies, in particular natural bispecific antibodies (κλ-bodies), for the treatment of cancer. The company focuses on the development of therapeutics that specifically target tumor cells by targeting specific molecules such as CD47 and CD28.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered6
Bispecific antibodies
Native, non-genetically engineered human bispecific antibodies based on κλ bodies; development and clinical pipeline for CD47 and CD28 targeting, as well as additional bispecific programs.
Antibody development and partnerships
Access to technology, generation of bispecific leads, and joint further development of projects across various therapeutic areas, particularly in immuno-oncology.
CD47 targeting
Selective blockade of CD47 on tumors with bispecific antibodies; tumour-directed approaches to spare normal cells.
CD28 targeting
Tumour-dependent CD28 co-stimulation via bispecific antibodies; activation of T cells only in the tumour microenvironment, including in combination with PD-L1-directed approaches.
κλ body discovery
Identification of antibodies from heavy-chain libraries, co-expression of heavy and two light chains, direct testing in cell culture supernatant, and purification by standard affinity chromatography.
Immuno-oncology development
Development of bispecific immuno-oncology programs with CD47 and CD28 targeting, as well as preclinical and clinical candidates against solid tumors and B-cell malignancies.
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

NovImmune SA

Trust & reputation

ranQ Trust Score of NovImmune SA: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 100% · As of October 2026

NovImmune SA scores 49.8 out of 100 points in the Reputation area of the ranQ Trust Score. This area carries 42% of the weighting.
x
CriterionValueWeight
  • Review quality: The average rating across all connected sources, smoothed against the industry mean. So 5.0 stars from three reviews do not outrank 4.7 from three hundred.68.224%
  • Review volume: The number of reviews across all sources. The scale is logarithmic: the first reviews count the most, and the maximum is reached at 50 reviews.17.610%
  • Review recency: The age of the most recent review. Two-year-old reviews deliberately sit in the middle, because that is normal for Swiss SMEs. Only after three years without a new voice does the value drop markedly.35.08%
NovImmune SA scores 94.3 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.100.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.90.07%
NovImmune SA scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
NovImmune SA scores 55.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.10.04%
Qualifications+0.00

NovImmune SA reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». The rating draws, among other things, on 5.0 out of 5 stars from 1 customer reviews. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Reviews

Aggregated rating

Aggregated rating
5
of 5

Aggregated from 1 reviews across all connected sources

Sources
GGoogle51
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Press

Media

August 16, 2022Media
Light Chain Bioscience doses first patients with solid cancers
startupticker.ch

Knowledge

No knowledge articles yet

Once NovImmune SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

NovImmune SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank NovImmune SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of NovImmune SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Chemin du Pré-Fleuri 15
1228 Plan-Les-Ouates
Opening hours
Mon
08:30 - 17:00
Tue
08:30 - 17:00
Wed
08:30 - 17:00
Thu
08:30 - 17:00
Fri
08:30 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-104.261.899
Founded
1998 · 28 years
Last commercial register change
April 28, 2026
Employees
51 to 100
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    KB
    KBI Biopharma SA
    Plan-Les-Ouates
    VF
    Vaccine Formulation Institute SA
    Plan-Les-Ouates
    IS
    iOnctura SA
    Geneva
    MM
    MMV MEDICINES FOR MALARIA VENTURE
    Cointrin
    OP
    OM Pharma SA
    Meyrin
    AT
    Atopia Therapeutics SA
    Geneva
    KK
    Kyowa Kirin Sàrl
    Geneva
    LP
    Labatec Pharma SA
    Meyrin